A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations
Guillermo Suay(Hospital Universitari i Politècnic La Fe), Óscar Juan(Hospital Universitari i Politècnic La Fe), Paloma Martín-Martorell(Hospital Clínico Universitario de Valencia), Amelia Insa(Hospital Clínico Universitario de Valencia), Francisco Aparisi(Leitat Technological Center), José David Cumplido-Burón(Hospital Quirón Torrevieja), María Díaz(Columbia University), Aitor Azkárate(Hospital Universitario Insular de Gran Canaria), M. Guirado(Hospital General Universitario de Elche), María José Domper-Arnal(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), José González(INCLIVA Health Research Institute), Alfredo Sánchez-Hernández(Fundación Hospital Provincial de Castellón), Sarai Palanca(Hospital Universitari i Politècnic La Fe), J. Garde(Hospital Arnau de Vilanova)
Cited by 2
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries
|World Journal of Gastroenterology|2015|1k
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
|Journal of Clinical Oncology|2024|211
Gastrointestinal and cardiovascular adverse events associated with NSAIDs
|Expert Opinion on Drug Safety|2021|134